Agios Reports New, Final Data from Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers for AG-348, an Investigational Medicine for Pyruvate Kinase (PK) Deficiency
June 12, 2015 at 06:03 AM EDT
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, ...
